Latest news
{{'2021-04-21T13:52:22Z' | dateFormatFilter}}
Novo Nordisk to initiate phase 3a development in obesity with oral semaglutide
Read more
{{'2021-03-26T12:57:59Z' | dateFormatFilter}}
Saxenda® recommended for approval by European Medicines Agency committee for the treatment of obesity in adolescents aged 12–17 years
Read more
{{'2021-03-25T16:12:43Z' | dateFormatFilter}}
Correction: Resolutions from the Annual General Meeting of Novo Nordisk A/S
Read more
.jpg.corpimgt.48.48.jpeg)
Career Opportunities
Here are our current job openings. If there is not a job you are looking for, you are welcome to create a job agent or a candidate profile.
Investors
Share price
{{priceData.date}} {{priceData.time}}
